Adam Maeder

Q: What is Adam Maeder's success rate?

Adam Maeder currently has a success rate of 98.77886193878975.

Q: What is the average return of Adam Maeder's calls?

Their stock ratings have generated an average return of 9.484235588731503.

Piper Sandler | Healthcare

Adam Maeder is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #1285 out of 4771 analysts, they have issued 33 stock ratings with a success rate of 98.78% and an average return of 9.48%.

Adam Maeder has a well-established track record, with 33 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 98.78% and an average return of 9.48%, underscoring their expertise and ability to identify winning opportunities for investors.

#1285

Out of 4771

Total Ratings

+98.78%

Success Rate

+9.48%

Average Return

Recent Ratings Analysis

LIVN

Buy

Sep 02, 2026

Target

$90.00

Current

$78.18

Performance

-5.12%

Adam Maeder rated LIVN as Overweight on Sep 02, 2026, setting a price target of 90. The stock has underperformed, dropping 5.12% despite the bullish target of 90.

INSP

Hold

Aug 04, 2026

Target

$60.00

Current

$68.12

Performance

6.21%

On Aug 04, 2026, INSP was given a Neutral rating by Adam Maeder, with a target price of 60. The stock rallied from 68.12 to 68.12 after the Hold rating, surprising to the upside.

GKOS

Buy

Jul 30, 2026

Target

$195.00

Current

$170.38

Performance

1.10%

GKOS received a Overweight rating from Adam Maeder on Jul 30, 2026, aiming for 195. Price action was muted, as shares hovered around 170.38 despite the bullish outlook.

EW

Buy

Jul 24, 2026

Target

$101.00

Current

$86.77

Performance

5.01%

On Jul 24, 2026, Adam Maeder published a Overweight outlook on EW, with a target of 101. Shares gained 5.01%, underscoring the accuracy of the bullish outlook toward 101.

ISRG

Buy

Jul 17, 2026

Target

$470.00

Current

$360.46

Performance

4.35%

Adam Maeder on Jul 17, 2026 assigned ISRG a Overweight rating, with a price target of 470. The recommendation remains pending validation as shares consolidate around 360.46.

ABT

Buy

Jul 17, 2026

Target

$118.00

Current

$103.37

Performance

2.67%

On Jul 17, 2026, Adam Maeder reaffirmed ABT with a Overweight rating, targeting 118. Market indecision has kept the 118 target in a holding pattern.

STAA

Hold

May 14, 2026

Target

$33.00

Current

$23.42

Performance

-26.84%

STAA was rated Neutral by Adam Maeder on May 14, 2026, with a price objective of 33. Investors who stayed cautious avoided some of the 26.84% decline.

NYXH

Buy

May 13, 2026

Target

$7.00

Current

$1.50

Performance

-51.30%

On May 13, 2026, Adam Maeder initiated coverage on NYXH with a Overweight rating and target of 7. The Buy call has yet to be validated as shares remain 5.50 away from the target.

STXS

Buy

May 13, 2026

Target

$3.50

Current

$1.30

Performance

-29.73%

Adam Maeder issued a Overweight recommendation for STXS on May 13, 2026, price target set at 3.5. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

NSPR

Buy

May 05, 2026

Target

$3.00

Current

$0.78

Performance

-29.10%

On May 05, 2026, NSPR was evaluated by Adam Maeder, who gave a Overweight rating and target of 3. Investors saw limited payoff as shares fell short of the 3 target.

RXST

Hold

Feb 26, 2026

Target

$11.00

Current

$5.96

Performance

-24.75%

Adam Maeder rated RXST as Neutral on Feb 26, 2026, setting a price target of 11. The cautious Hold call aligned with subsequent weakness, as shares slipped 24.75%.

TCMD

Buy

Feb 18, 2026

Target

$42.00

Current

$22.32

Performance

-32.47%

On Feb 18, 2026, TCMD was given a Overweight rating by Adam Maeder, with a target price of 42. Despite the Buy call, shares fell from 22.32 to 22.32, challenging the optimistic stance.

RMD

Hold

Jan 30, 2026

Target

$275.00

Current

$219.58

Performance

-14.99%

RMD received a Neutral rating from Adam Maeder on Jan 30, 2026, aiming for 275. The Hold stance proved prudent, with the market softening by 14.99%.

SGHT

Buy

Jan 05, 2026

Target

$9.00

Current

$8.01

Performance

3.83%

On Jan 05, 2026, Adam Maeder published a Overweight outlook on SGHT, with a target of 9. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 8.005.

RBOT

Hold

Aug 13, 2025

Target

$7.00

Current

$0.04

Performance

-99.50%

Adam Maeder on Aug 13, 2025 assigned RBOT a Neutral rating, with a price target of 7. The call successfully avoided chasing as shares lost 99.50%.

NVRO

Hold

Feb 07, 2025

Target

$5.85

Current

$5.84

Performance

2.10%

On Feb 07, 2025, Adam Maeder reaffirmed NVRO with a Neutral rating, targeting 5.85. The neutral call matched muted market action of 2.10%.

NARI

Hold

Jan 07, 2025

Target

$80.00

Current

$79.97

Performance

0.65%

NARI was rated Neutral by Adam Maeder on Jan 07, 2025, with a price objective of 80. Flat performance suggests the Hold view was reasonable.

SILK

Hold

May 01, 2024

Target

$20.00

Current

$27.49

Performance

36.36%

On May 01, 2024, Adam Maeder initiated coverage on SILK with a Neutral rating and target of 20. The Hold stance underestimated the stock’s strength as it gained 36.36%.

Frequency Asked Questions

Who is Adam Maeder?

Adam Maeder is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Adam Maeder's success rate?

Adam Maeder currently has a success rate of +98.78%.

How many ratings has Adam Maeder issued?

Adam Maeder has issued 33 stock ratings so far.

What is the average return of Adam Maeder's calls?

Their stock ratings have generated an average return of +9.48%.

What is Adam Maeder's ranking?

Adam Maeder is ranked #1285 out of 4771 analysts.

What types of ratings does Adam Maeder give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Adam Maeder?

You can follow Adam Maeder by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Adam Maeder?

Their latest rating was a Buy on LIVN issued on 2026-09-02.